Setmelanotide

Dosing from the Literature

Published for genetic obesity: the label's 2–3 mg a day for adults and children from age 6, built up gradually, and 0.5–2 mg a day by body weight for ages 2–5 (Imcivree label). Not published: an approved dose for ordinary obesity, which the label excludes (Imcivree label).

The FDA label sets the doses by condition, age and, under age 6, body weight. Each starts low and is raised after 2 weeks if tolerated, and the label calls for watching for gastrointestinal reactions while the dose is started and raised (Imcivree label).

What It Is

Setmelanotide is a cyclic eight-amino-acid peptide developed by Rhythm Pharmaceuticals as a selective agonist of the melanocortin-4 receptor (MC4R), the terminal receptor of the hypothalamic (brain's hormonal control center) leptin-melanocortin satiety pathway. It was approved by the U.S. Food and Drug Administration on November 25, 2020, under the brand name Imcivree®, initially for chronic weight management in adults and pediatric patients aged 6 and older with obesity caused by biallelic (homozygous or compound heterozygous) variants in POMC, PCSK1, or LEPR — three rare autosomal recessive conditions that collectively affect fewer than a few hundred genetically confirmed patients in the United States. In June 2022 the indication was expanded to Bardet-Biedl syndrome (BBS), a ciliopathy in which impaired primary-cilium signaling disrupts melanocortin pathway function. In December 2024 the label was further expanded to include patients aged 2 to 5 years based on the VENTURE Phase 3 trial, and in March 2026 to acquired hypothalamic obesity in patients aged 4 and older (Drugs@FDA; Imcivree label).

Structurally, setmelanotide is a rationally engineered analog of α-melanocyte stimulating hormone (α-MSH), the endogenous MC4R (the receptor that controls appetite) ligand. The molecule carries key modifications — a cyclic disulfide bridge and D-amino acid substitutions — that confer MC4R selectivity and resistance to peptide degradation. The molecular weight is approximately 1,117 Da and the half-life after SubQ injection is approximately 11 hours; the label gives it once a day (Imcivree label). It is supplied by Rhythm Pharmaceuticals as a 10 mg/mL solution in multiple-dose vials for a single patient, injected under the skin by the patient or a caregiver after training (Imcivree label).

What makes setmelanotide historically significant is that it is the first therapeutic to directly address the biology of specific monogenic and syndromic obesities. Patients with POMC, PCSK1, LEPR, or BBS-related obesity experience profoundly disruptive hyperphagia from early childhood that is fundamentally resistant to diet, exercise, behavioral intervention, and standard pharmacotherapy — because the defect lies in the brain's ability to register satiety rather than in willpower or lifestyle. Setmelanotide operates downstream of the broken upstream signaling by engaging MC4R directly, restoring the signal that says "you are full." For families who have lived with a child who cannot feel satisfied by any amount of food, the effect of setmelanotide on hunger can be transformative in a way that is categorically different from weight loss in common obesity.

Setmelanotide is not indicated for common polygenic obesity. A Phase 2 trial in general obesity produced only modest weight reduction (2.0% on setmelanotide vs 0.3% on placebo over 90 days; NCT01749137, ClinicalTrials.gov results) — an effect size substantially below what GLP-1 agonists (semaglutide, tirzepatide) and the newer triple-agonist incretins (retatrutide) achieve in the same setting. This outcome is consistent with the biology: in common obesity, the leptin-melanocortin pathway is fundamentally intact, so adding an MC4R agonist does not rescue a biology that is not broken.

Mechanism of Action

The leptin-melanocortin pathway plays a key role in the hypothalamus's control of food intake (Huvenne et al., 2016). Setmelanotide activates MC4R, the receptor through which POMC-derived peptides reduce food intake and body weight (Collet et al., 2017).

• Leptin-melanocortin satiety pathway — Leptin activates proopiomelanocortin (POMC) neurons in the hypothalamus's arcuate nucleus, which produce α-MSH (the hormone that tells skin to tan); α-MSH activates MC4R in the paraventricular nucleus, producing a satiety signal (Huvenne et al., 2016). PCSK1, which encodes the enzyme proconvertase 1, is one of the pathway's genes, with those for leptin, its receptor (LEPR) and POMC (Huvenne et al., 2016). MC4 receptors in the brain help regulate hunger, satiety and energy expenditure (Imcivree label).
• Genetic defects create hyperphagia — Biallelic variants in genes of the MC4R pathway, such as POMC, PCSK1 and LEPR, can cause severe early-onset obesity (Clément et al., 2020; Huvenne et al., 2016). People with POMC defects have hyperphagia (extreme hunger) and extreme early-onset obesity, with pale skin and low cortisol from the missing POMC-derived hormones (Kühnen et al., 2016).
• MC4R agonism (primary mechanism) — MC4R is a Gαs-coupled receptor; in cell assays, setmelanotide raised cAMP through it at nanomolar concentrations and was 10–20 times more potent than the body's own α-MSH (Collet et al., 2017). The label says that, on nonclinical evidence, it may re-establish MC4 receptor pathway activity where the receptor is not activated enough (Imcivree label). In the POMC and LEPR Phase 3 trials, hunger scores fell along with body weight (Clément et al., 2020).
• Selectivity profile — In cell assays, setmelanotide needed concentrations about 20 times higher to activate MC1R (the receptor that controls skin pigment) and MC3R (a melanocortin receptor for energy balance), over 1 µM for MC5R (a melanocortin receptor in glands), and had no activity at MC2R (the ACTH receptor on adrenal glands) (Collet et al., 2017). Activating MC1R on melanocytes increases melanin and skin pigmentation, which occurred in most patients in the trials, and setmelanotide can darken existing moles (nevi) and cause new ones (Imcivree label).
• Bardet-Biedl syndrome mechanism — BBS arises from impaired function of the primary cilium (Haqq et al., 2022), and BBS proteins are needed to place LEPR correctly in the hypothalamus (Huvenne et al., 2016). Impaired cilial signalling in the MC4R pathway might contribute to the obesity, though the mechanism is not fully understood (Haqq et al., 2022); the label applies its nonclinical rationale, that setmelanotide may re-establish MC4 receptor pathway activity, to BBS (Imcivree label).
• Energy expenditure — In 12 otherwise healthy people with obesity, short-term setmelanotide increased resting energy expenditure and shifted fuel use toward fat. The label attributes its weight loss, on nonclinical evidence, to both lower calorie intake and higher energy expenditure (Imcivree label).
• Sexual function effects — Spontaneous and more frequent penile erections occurred in male trial patients, and the label carries a warning on disturbed sexual arousal (Imcivree label).
• Pharmacokinetics — Daily SubQ administration; peak level a median 8 hours after the dose; half-life about 11 hours; steady state within 2 days. The label expects it to be broken down into small peptides; about 39% of a dose leaves unchanged in the urine, and in vitro it showed low potential for CYP450 interactions (Imcivree label).
• Pathway-specific therapeutic — Obese MC4R variant carriers lost weight in a 28-day Phase 1b trial, but patients with POMC defects upstream of MC4R lost significantly more than MC4R-deficient patients or obese controls, and MC4R knockout mice did not respond (Collet et al., 2017). MC4R variants themselves are found in 2–3% of children and adults with obesity, mostly heterozygous (Huvenne et al., 2016). The label excludes general obesity and obesity from other genetic syndromes (Imcivree label).

What the Research Shows

The approvals rest on small trials: two single-arm Phase 3 trials in POMC or PCSK1 deficiency (10 patients) and LEPR deficiency (11 patients) (Clément et al., 2020), a Phase 3 trial in Bardet-Biedl syndrome with a 14-week placebo-controlled period (Haqq et al., 2022), a single-arm trial in 12 children aged 2–5 (Argente et al., 2025) and a 142-patient placebo-controlled trial in acquired hypothalamic obesity (Imcivree label). Mean weight loss at about 1 year was 23% in POMC or PCSK1 deficiency and 10% in LEPR deficiency (Imcivree label).

• POMC/LEPR deficiency Phase 3 (Clément et al., Lancet Diabetes Endocrinol 2020; PMID 33137293) — Two single-arm, open-label, multicenter Phase 3 trials. POMC cohort (n=10): 80% of evaluable patients (8/10) achieved ≥10% body weight loss at approximately 1 year. Mean BMI reduction 25.6%. Hunger scores substantially reduced. LEPR cohort (n=11): 45% achieved ≥10% body weight loss; mean BMI reduction 12.5%. Basis for 2020 FDA approval.
• Bardet-Biedl / Alström Phase 3 (Haqq et al., Lancet Diabetes Endocrinol 2022; PMID 36356613) — 38 patients enrolled (32 BBS, 6 Alström). Randomized 1:1 to setmelanotide vs placebo for 14 weeks followed by 52 weeks open-label setmelanotide. In patients aged ≥12 with BBS, 32.3% (95% CI 16.7–51.4; p=0.0006) achieved ≥10% body weight loss at 52 weeks. Alström cohort did not achieve statistical significance. Basis for June 2022 FDA approval for BBS.
• VENTURE pediatric Phase 3 (Argente et al., Lancet Diabetes Endocrinol 2025; PMID 39549719) — 12 patients aged 2–5 years with POMC, PCSK1, LEPR, or BBS-related obesity. 52-week open-label. Supported 2024 label expansion to children aged 2 and above.
• Common obesity Phase 2 — In a 90-day Phase 2 trial in 74 people with general obesity, weight fell 2.0% on setmelanotide and 0.3% on placebo (NCT01749137; ClinicalTrials.gov results). Defined the boundary of setmelanotide's utility.
• Quality of life (Kühnen et al., Orphanet J Rare Dis 2022) — Quality-of-life outcomes from the POMC and LEPR Phase 3 trials; significant patient-reported improvement in multiple domains.
• Natural history comparison — Matched-cohort analysis against Barth BBS natural history data (Forsythe et al.) provides supportive evidence that setmelanotide's effect exceeds what the untreated patient trajectory would predict.
• Long-term extension data — Open-label extension data beyond 52 weeks confirms durability of hunger reduction and weight loss over multiple years in continuing responders.
• Hunger reduction as distinct endpoint — Across all trials, patient- and caregiver-reported hunger scores (Daily Hunger Questionnaire) improved more rapidly and reliably than body weight, supporting the conceptual frame that setmelanotide primarily treats hyperphagia with weight loss as secondary outcome.
• Hypothalamic obesity research — In a randomized, placebo-controlled Phase 3 trial in 142 patients aged 4 and older with acquired hypothalamic obesity, from hypothalamic injury or dysfunction rather than genetics, BMI fell 15.8% on setmelanotide and rose 2.6% on placebo after 52 weeks (NCT05774756). FDA approved the indication in March 2026 (Imcivree label; Drugs@FDA).

Human Data

Setmelanotide's human database is narrow but deep — limited in size by the rarity of the target conditions but methodologically rigorous in design.

• NCT02896192 (POMC Phase 3) — 10 patients with biallelic POMC or PCSK1 deficiency. Single-arm, 4-week placebo-controlled withdrawal period, 52-week treatment.
• NCT03287960 (LEPR Phase 3) — 11 patients with biallelic LEPR deficiency. Same design as POMC trial.
• NCT03746522 (BBS/Alström Phase 3) — 38 patients with BBS or Alström syndrome. Randomized placebo-controlled 14-week lead-in followed by 52-week open-label.
• VENTURE (NCT04966741) — Pediatric 2–5 year Phase 3 in MC4R-pathway-associated obesity.
• Hypothalamic obesity Phase 3 (NCT05774756) — 142 patients aged 4 and older with acquired hypothalamic obesity; randomized, double-blind, placebo-controlled, with up to 8 weeks of dose titration and 52 weeks of treatment. The basis for the March 2026 approval (Imcivree label; Drugs@FDA).
• Real-world post-marketing — Since 2020 approval, substantial real-world patient-level experience has accumulated through the specialty prescribing channel. Patient registries document durability, sustained hunger reduction, and emergence of long-term adverse event profile consistent with the trial data.
• Case reports in expanded indications — Published case-level evidence in heterozygous POMC variant carriers, patients with SIM1 variants, and select other MC4R-pathway disorders; outcomes are variable and framed as investigational.
• Pediatric safety extension — Open-label extension of POMC/LEPR trials in pediatric patients supporting continued dosing safety and durability.
• Common obesity Phase 2 (negative) — The negative common-obesity Phase 2 is itself informative: it established the limits of the indication and guided Rhythm's pivot to the precision-medicine approach.

Setmelanotide is therefore a case study in precision-medicine drug development: a mechanistically rational compound with modest effect in the general population but transformative effect in a precisely defined genetic subpopulation.

Reconstitution & Storage

Imcivree® is supplied by Rhythm Pharmaceuticals as a sterile 10 mg/mL solution in a 1 mL multiple-dose vial for a single patient; it is not a powder, so there is nothing to reconstitute (Imcivree label).

• Storage (unopened) — The label lists 2–8°C (36–46°F) in the original carton, away from light, until the expiry date; once out of the refrigerator, up to 30 days at 2–25°C (36–77°F), with brief excursions to 30°C (86°F). Its instructions say not to shake the vial (Imcivree label).
• Storage (in-use) — The label lists 2–8°C for an opened vial, or 2–25°C if needed, and says it is thrown away 30 days after first opening, even with medicine left (Imcivree label).
• Injection technique — The label describes injection under the skin of the abdomen (at least 2 inches from the navel), the front of the thigh or the back of the upper arm, at a different site each day, with a 1 mL syringe and a 28- or 29-gauge needle (Imcivree label).
• Timing — The label gives it once a day at the beginning of the day, with or without food (Imcivree label).
• Appearance — Clear to slightly opalescent, colorless to slightly yellow; the label says not to use a vial that is cloudy, discolored or has particles (Imcivree label).

→ Calculator — vial-to-syringe math

Side Effects & Risks

The label's adverse-reaction figures come from five trials, the largest with 142 patients, and from reports after approval (Imcivree label).

• Skin hyperpigmentation (58–83% across the label's trials) — Generalized or patchy skin darkening, through activation of MC1R on melanocytes; it reverses after stopping, and the label calls for a full-body skin exam before starting and periodically during treatment (Imcivree label).
• Injection site reactions (51–96% in the BBS, POMC/PCSK1/LEPR and under-6 trials) — Redness, itching, swelling, pain, hardening and bruising (Imcivree label).
• Nausea, vomiting, diarrhea — Nausea in 26–56%, vomiting in 19–58% and diarrhea in 14–37% of patients in the label's trial tables (Imcivree label). In the BBS trial, all nausea and vomiting was mild or moderate and infrequent after the first month (Haqq et al., 2022).
• Spontaneous penile erections / sexual arousal disturbance — Spontaneous erections in 23% and 25% of male patients in the POMC/PCSK1/LEPR and BBS trials, 8% of children aged 2–5, and 7% of patients with acquired hypothalamic obesity (4% on placebo); the label's patient information also lists unwanted sexual arousal in women. The label asks prescribers to warn patients, and an erection lasting more than 4 hours needs emergency care (Imcivree label).
• Depression and suicidal ideation — A warning on the label. Depression occurred in 26% and suicidal ideation in 11% of the 27 patients in the POMC/PCSK1/LEPR trials, and depressed mood in 8% of children aged 2–5. Patients with a history of depression or suicidal ideation may be at higher risk; the label calls for monitoring mood and says to consider stopping if suicidal thoughts or significant, persistent depression occur (Imcivree label).
• Pigmented skin lesion changes — New moles, or existing ones growing or darkening: 14–33% of patients across the label's trials, and 15% vs 6% on placebo in acquired hypothalamic obesity; the label's skin exams monitor these lesions. Its only contraindication is a prior serious hypersensitivity reaction to setmelanotide or its ingredients (Imcivree label).
• Hypersensitivity reactions — Serious reactions, including anaphylaxis, reported after approval, generally within minutes to hours of an injection; their frequency is unknown (Imcivree label).
• Headache — 41% in the POMC/PCSK1/LEPR trials, 7% in the BBS trial, and 37% vs 31% on placebo in acquired hypothalamic obesity (Imcivree label).
• Sleep changes — Insomnia in 15% of the 27 patients in the POMC/PCSK1/LEPR trials (Imcivree label).
• Pregnancy — No human data. The label says to stop it when pregnancy is recognized unless the benefits outweigh the risks to the fetus, and notes that weight loss offers no benefit in pregnancy and may harm the fetus. It was not teratogenic in rats or rabbits; in rabbits, fetal losses rose only at doses toxic to the mother (Imcivree label).
• Lactation — The label does not recommend it while breastfeeding; setmelanotide passes into rat milk, and human data are lacking (Imcivree label).
• Drug interactions — The label expects setmelanotide to be broken down into small peptides; in vitro, it showed low potential for interactions through CYP450 enzymes, transporters or protein binding, and no clinical interaction study has been done (Imcivree label).
• WADA status — Setmelanotide is not named on the 2026 Prohibited List, and its S0 clause, which covers substances no government has approved for human use, does not reach it: FDA approved it in 2020 (World Anti-Doping Agency, 2026).
• No boxed warning — The label has no boxed warning. Its warnings cover sexual arousal, depression and suicidal ideation, hypersensitivity, skin pigmentation and moles and, in acquired hypothalamic obesity, acute adrenal insufficiency (5% of treated patients, none on placebo) and low or high blood sodium in patients with central diabetes insipidus (Imcivree label).

Bloodwork & Monitoring

The Imcivree label sets no blood test for every patient; it lists the checks below (Imcivree label).

• Genetic testing — The POMC, PCSK1 and LEPR indications require genetic testing that shows variants read as pathogenic, likely pathogenic or of uncertain significance; no FDA-approved test for these genes exists. BBS is a clinical diagnosis, with genetic confirmation to be considered under age 6, and the label names no genetic test for acquired hypothalamic obesity (Imcivree label).
• Skin exams — A full-body skin exam before starting and periodically during treatment, for existing and new pigmented lesions; the label sets no interval (Imcivree label).
• Mood — Monitoring for new or worsening depression, suicidal thoughts or behavior, or unusual changes in mood or behavior; the label names no screening tool or schedule (Imcivree label).
• What the trials measured — Weight or BMI, BMI Z score in children, and, from age 12, daily maximal hunger on an 11-point diary scale (Daily Hunger Questionnaire item 2); in the trial of children aged 2–5, caregivers rated hunger (Imcivree label; Argente et al., 2025).
• Erections — Warning patients that spontaneous erections can occur, and that an erection lasting more than 4 hours needs emergency care (Imcivree label).
• Acquired hypothalamic obesity — Serum sodium when fluid intake or hydration changes in patients with central diabetes insipidus, and watching for acute adrenal insufficiency in those with secondary adrenal insufficiency (Imcivree label).

Commonly Stacked With

No registered trial has tested setmelanotide in combination with another drug (ClinicalTrials.gov, October 2026).

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching setmelanotide often also look at these:

Next Steps

References

1. Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960-970. PMID: 33137293.
2. Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clément K, Argente J. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859-868. PMID: 36356613.
3. Argente J, Verge CF, Okorie U, Fennoy I, Kelsey MM, Cokkinias C, Scimia C, Lee HM, Farooqi IS. Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(1):29-37. PMID: 39549719.
4. Markham A. Setmelanotide: First Approval. Drugs. 2021;81(3):397-403. PMID: 33638809.
5. Kühnen P, Clément K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, Mai K, Blume-Peytavi U, Grüters A, Krude H. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. N Engl J Med. 2016;375(3):240-246. PMID: 27468060.
6. Clément K, Biebermann H, Farooqi IS, Van der Ploeg L, Wolters B, Poitou C, Puder L, Fiedorek F, Gottesdiener K, Kleinau G, Heyder N, Scheerer P, Blume-Peytavi U, Jahnke I, Sharma S, Mokrosinski J, Wiegand S, Müller A, Weiß K, Mai K, Spranger J, Grüters A, Blankenstein O, Krude H, Kühnen P. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551-555. PMID: 29736023.
7. Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, Henning E, Poitou-Bernert C, Oppert JM, Tounian P, Marchelli F, Alili R, Le Beyec J, Pépin D, Lacorte JM, Gottesdiener A, Bounds R, Sharma S, Folster C, Henderson B, O'Rahilly S, Stoner E, Gottesdiener K, Panaro BL, Cone RD, Clément K, Farooqi IS, Van der Ploeg LHT. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017;6(10):1321-1329. PMID: 29031731.
8. Kühnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, Gnanasakthy A, Poitou C, Krabusch PM, Stewart M, Clément K. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency. Orphanet J Rare Dis. 2022;17(1):38. PMID: 35123544.
9. Dubern B, Lourdelle A, Clément K. Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers. JCEM Case Rep. 2023;1(3):luad041. PMID: 37908575.
10. Forsythe E, Haws RM, Argente J, Beales P, Martos-Moreno GÁ, Dollfus H, Chirila C, Gnanasakthy A, Buckley BC, Mallya UG, Clément K, Haqq AM. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet J Rare Dis. 2023;18(1):12. PMID: 36647077.
11. Ryan DH. Setmelanotide: what it means for clinical care of patients with obesity. Lancet Diabetes Endocrinol. 2020;8(12):933-935. PMID: 33137294.
12. Huvenne H, Dubern B, Clément K, Poitou C. Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016. Obes Facts. 2016;9(3):158-173. PMID: 27241181.
13. US Food and Drug Administration. IMCIVREE (setmelanotide) injection, for subcutaneous use — Full Prescribing Information. Initial approval November 2020; label updates June 2022 and 2024.
14. Rhythm Pharmaceuticals. IMCIVREE® prescribing information and patient support program materials. 2024–2026.
15. ClinicalTrials.gov. Setmelanotide program trial listings: NCT02896192 (POMC), NCT03287960 (LEPR), NCT03746522 (BBS/Alström), NCT04966741 (VENTURE pediatric 2–5 yrs).
16. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
17. Rhythm Pharmaceuticals. IMCIVREE (setmelanotide) injection, for subcutaneous use, prescribing information. DailyMed set ID 70c3ccf7-4df0-4c75-ba07-fede9970c8d9 (SPL version 14, version effective April 1, 2026). dailymed.nlm.nih.gov. Read October 4, 2026.
18. World Anti-Doping Agency. Prohibited List 2026 (in effect January 1, 2026). S0, Non-approved substances. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf. Read October 3, 2026.

Related Research

• 5-Amino-1MQNNMT Inhibitor
• AdipotideExperimental Pro-Apoptotic Chimera
• AICARAMPK Activator / Exercise Mimetic
• AOD-9604hGH C-Terminal Fragment / Lipolytic
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.